ARIAD Pharma (ARIA) Receives Payments from Bellicum (BLCM)

As previously disclosed, in October 2014, ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) entered into an agreement with Bellicum Pharmaceuticals, Inc. (“Bellicum”) (Nasdaq: BLCM) to restructure and amend an existing license agreement between the companies for ARIAD’s cell-signaling technology. Under the terms of the agreement, ARIAD received $15 million upon execution of the agreement and was entitled to receive two payments of $20 million and $15 million by specified dates in the future in exchange for granting Bellicum a fully paid-up license to this technology and return of shares of Bellicum common stock owned by ARIAD. The second and third installment payments could be accelerated under certain circumstances and prepaid at any time. On December 23, 2014, Bellicum completed its initial public offering, and on December 29, 2014, Bellicum paid the $20 million and $15 million payments owed to ARIAD under the agreement and ARIAD returned the shares of Bellicum common stock owned by ARIAD.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• PPG names three segment leaders effective September 2026
• Silo Pharma acquires software assets from Parkview Consulting for stock